NCT06310915View on ClinicalTrials.gov

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

May 31, 2025

Conditions
Non-small Cell Lung Cancer Stage IIIB/IV
Interventions
DRUG

Navelbine oral,Pembrolizumab

Oral vinorelbine was administered three times weekly, and pembrolizumab was administered every 3 weeks

Trial Locations (1)

510000

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangdong

All Listed Sponsors
lead

Guangzhou Institute of Respiratory Disease

OTHER